U.S. Markets open in 8 hrs 1 min

Teva revenue falls short of estimates, lowers guidance as pandemic continue to weigh

·1 min read
Teva revenue falls short of estimates, lowers guidance as pandemic continue to weigh
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Teva Pharmaceutical Industries Ltd.'s shares slid 2.5% in premarket trade Wednesday, after the Israeli generics maker missed revenue estimates for the second quarter and lowered guidance, citing the continued impact of the pandemic. Teva posted net income of $207 million, or 19 cents a share, in the quarter, up from $140 million, or 13 cents a share, in the year-earlier period. Adjusted per-share earnings came to 59 cents, matching the FactSet consensus. Revenue rose to $3.910 billion from $3.87